Functional antagonism: tolerance produced by inhaled beta 2 agonists
about
Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroidLong-acting beta2-agonists for stable chronic asthmaβ(2) -adrenoceptor agonists: current and future directionTolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial.Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary diseaseEnhancement of goblet cell hyperplasia and airway hyperresponsiveness by salbutamol in a rat model of atopic asthmaDecreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonistsAsthma--the changing face of drug therapy.Beta-adrenergic receptor polymorphisms and drug responses in asthma.Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol.Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism.Nebulised salbutamol administered during sputum induction improves bronchoprotection in patients with asthma.Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine.Effect of an inhaled glucocorticosteroid on mast cell and smooth muscle beta 2 adrenergic tolerance in mild asthma.Adverse effects of beta-agonists: are they clinically relevant?Differential desensitization of homozygous haplotypes of the beta2-adrenergic receptor in lymphocytesLong-acting bronchodilators with or without inhaled corticosteroids and 30-day readmission in patients hospitalized for COPD.Third-generation long-acting β₂-adrenoceptor agonists: medicinal chemistry strategies employed in the identification of once-daily inhaled β₂-adrenoceptor agonists.Oral beta2-agonist use by preschool children with asthma in East and Central Harlem, New York.Sympathomimetic enantiomers and asthma.Beta2-agonist tolerance and exercise-induced bronchospasm.
P2860
Q24246441-A957C2F6-8CA1-40CB-97F4-2D6068C9A3DFQ24247926-C7EABAD3-0954-4594-B1AB-09F5F1F27585Q24604047-41D50135-1906-44B4-A859-C5F5D9DBC3EDQ24816932-DF700FFC-F77A-4C9E-829C-54738ABC97CCQ28261960-F806F26C-4D5E-41C3-B388-0589D6D1B92DQ28345202-2703CF85-4A75-4A80-9BF4-0215189C7DFCQ28367141-E364AA3D-C470-4A62-B06F-431FE211FE7AQ33930453-AA35AA3D-3830-4492-8C3D-D98A47F7203AQ34612106-40891F07-7096-4ED1-BF09-B3D7307B9B45Q35532670-1C7C223C-A938-445E-9DA6-7C71A3F052A3Q35534065-E9F9BE10-2888-4F54-93FF-363A781593F3Q35536463-347EAFE3-5299-46C2-A2CE-723BDE2C35C7Q35563161-71165491-34A3-4A31-9FDA-6598DA3320EEQ35563951-56AB1373-024B-4EB6-B89E-F690337FE840Q35627643-03CD4687-5CBE-4590-9A2D-6C65DC26054CQ37282807-C2D474D4-62C1-4205-9DD9-271BE75DF103Q37626464-FDC70566-C4E2-4333-A352-99F162C4EAE8Q37937552-3959B24F-B957-4ADE-979B-DA2ED78297F0Q39744100-77B5C7E5-BBCA-4E4D-91E2-D6893CA78D1EQ41719837-CBBB3DAC-4277-4EF1-B9F9-87332F424D3DQ43961067-F5E90223-6A5F-48E7-AE44-70C7FFAD46D7
P2860
Functional antagonism: tolerance produced by inhaled beta 2 agonists
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Functional antagonism: tolerance produced by inhaled beta 2 agonists
@en
type
label
Functional antagonism: tolerance produced by inhaled beta 2 agonists
@en
prefLabel
Functional antagonism: tolerance produced by inhaled beta 2 agonists
@en
P2860
P356
P1433
P1476
Functional antagonism: tolerance produced by inhaled beta 2 agonists
@en
P2093
Cockcroft DW
Swystun VA
P2860
P304
P356
10.1136/THX.51.10.1051
P407
P577
1996-10-01T00:00:00Z